

**David Porter, Ph.D.**

Pharma Consultant

Vectech Pharmaceutical Consultants, Inc.

**TITLE:** Are the USP and Rapid Microbiological Methods Mutually Exclusive?

**BRIEF DESCRIPTION:**

Dr. Porter is a Pharma Consultant with Vectech Pharmaceutical Consultants, Inc. and was formerly the Director of General Policies and Requirements Division at the United States Pharmacopeia, who has previously served as a biostatistics group manager. He is a proven change agent and leader in technical problem solving with over 18 years experience in compendial activities, medical device, consumer product and pharmaceutical industry research, development and management. He has an innate ability to recognize and develop strengths in organizations and individuals and has combined his broad technical background in life sciences, biostatistics, and computer acumen in implementing policies.

He has numerous publications and patents, including but not limited to: Development of the Antimicrobial Effectiveness Test as USP Chapter <51> (2003), The Role of USP in the Microbiological Assessment of Parenteral Manufacturing (2004), Terminal Sterilization and Potential for Parametric Release (2005).

He has taught many courses on USP Analytical Microbiology COE, Harmonization of Pharmacopeil Biotechnology Products Testing, Equivalency of Microbiology Methods, Sterility Assurance Validation of Microbiological Methods, Rapid Microbiological Methods, and many more. Dr. Porter holds degrees in:

Post-doctoral fellow, Ohio State University, Case Western Reserve University

Ph.D. Zoology, University of California at Berkley

MS Biology, University of North Dakota

BS Biology, cum laude, department honors, Beloit College